Report : Asia Pacific Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
Treatment Segment to Dominate Asia Pacific Non-Alcoholic Steatohepatitis market Forecast to 2028 during 2019–2028
According to a new market research study on the Asia Pacific Non-Alcoholic Steatohepatitis market Forecast to 2028 –– by product, application, sales channel and countries is expected to reach US$ 4,040.30 million by 2028 from US$ 216.54 million in 2021. The market is estimated to grow at a CAGR of 51.9% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific Non-Alcoholic Steatohepatitis market along with the drivers and restraints pertaining to the market growth. Rising prevalence of NASH is the major factor driving the growth of the Asia Pacific Non-Alcoholic Steatohepatitis market. However, issues associated with stringent regulations related to Non-Alcoholic Steatohepatitis the growth of Asia Pacific Non-Alcoholic Steatohepatitis market.
The Asia Pacific Non-Alcoholic Steatohepatitis market segmented into prod uct, application, sales channel and country. Based on product type the Asia Pacific Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period of the Asia Pacific non-alcoholic steatohepatitis market in 2020.Based on application the Asia Pacific Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated Asia PacificNon-Alcoholic Steatohepatitis market in 2020. Based on sales channel the Asia Pacific Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated Asia PacificNon-Alcoholic Steatohepatitis market in 2020.Based on country, the Asia Pacific Non-Alcoholic Steatohepatitis market segmented into China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific. The China is dominated the Asia Pacific Non-Alcoholic Steatohepatitis market in 2020.
Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG,Galmed Pharmaceutical,GENFIT, Siemens Healthineers AG and Laboratory Corporation of America Holdings are among the leading companies in the Asia Pacific Non-Alcoholic Steatohepatitis market. For instance, Jun-2021 GENFIT announced poster presentation at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs). These presentation is on the clinical performance of GENFIT’s proprietary diagnostic technology NIS4 in diagnosing at-risk NASH in patients with type 2 diabetes. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in dynamic market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sales@businessmarketinsights.com